Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 30

1.

Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Kawarabayashi T, Younkin LH, Saido TC, Shoji M, Ashe KH, Younkin SG.

J Neurosci. 2001 Jan 15;21(2):372-81.

2.

Alzheimer's disease.

De-Paula VJ, Radanovic M, Diniz BS, Forlenza OV.

Subcell Biochem. 2012;65:329-52. doi: 10.1007/978-94-007-5416-4_14. Review.

PMID:
23225010
3.

β-Amyloid peptides and amyloid plaques in Alzheimer's disease.

Gouras GK, Olsson TT, Hansson O.

Neurotherapeutics. 2015 Jan;12(1):3-11. doi: 10.1007/s13311-014-0313-y. Review.

4.

Amyloid-β peptide: Dr. Jekyll or Mr. Hyde?

Puzzo D, Arancio O.

J Alzheimers Dis. 2013;33 Suppl 1:S111-20. Review.

5.

Maximizing the potential of plasma amyloid-beta as a diagnostic biomarker for Alzheimer's disease.

Oh ES, Troncoso JC, Fangmark Tucker SM.

Neuromolecular Med. 2008;10(3):195-207. doi: 10.1007/s12017-008-8035-0. Epub 2008 Jun 10. Review.

6.

Defining the earliest pathological changes of Alzheimer's disease.

Vickers JC, Mitew S, Woodhouse A, Fernandez-Martos CM, Kirkcaldie MT, Canty AJ, McCormack GH, King AE.

Curr Alzheimer Res. 2016;13(3):281-7. Review.

7.

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease.

Hampel H, Shen Y, Walsh DM, Aisen P, Shaw LM, Zetterberg H, Trojanowski JQ, Blennow K.

Exp Neurol. 2010 Jun;223(2):334-46. doi: 10.1016/j.expneurol.2009.09.024. Epub 2009 Oct 6. Review.

8.

Traumatic brain injury and amyloid-β pathology: a link to Alzheimer's disease?

Johnson VE, Stewart W, Smith DH.

Nat Rev Neurosci. 2010 May;11(5):361-70. doi: 10.1038/nrn2808. Review.

9.

Commentary: is Alzheimer's disease uniquely human?

Finch CE, Austad SN.

Neurobiol Aging. 2015 Feb;36(2):553-5. doi: 10.1016/j.neurobiolaging.2014.10.025. Epub 2014 Oct 23. Review.

10.

Abeta aggregation and possible implications in Alzheimer's disease pathogenesis.

Bharadwaj PR, Dubey AK, Masters CL, Martins RN, Macreadie IG.

J Cell Mol Med. 2009 Mar;13(3):412-21. doi: 10.1111/j.1582-4934.2009.00609.x. Review.

11.

[Biomarker and imaging of Alzheimer's disease].

Kawarabayashi T, Shoji M.

No To Shinkei. 2005 Oct;57(10):839-52. Review. Japanese. No abstract available.

PMID:
16277229
12.

Gd-DOTA-anti-Aβ42-F(ab’)2-antibody fragment (putrescine)n.

Zhang H.

Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004-2013.
2008 Nov 7 [updated 2008 Dec 22].

13.

Amyloid beta plaque: a culprit for neurodegeneration.

Gupta A, Goyal R.

Acta Neurol Belg. 2016 Dec;116(4):445-450. Epub 2016 Apr 27. Review.

PMID:
27118573
14.

The Aβ oligomer hypothesis for synapse failure and memory loss in Alzheimer's disease.

Ferreira ST, Klein WL.

Neurobiol Learn Mem. 2011 Nov;96(4):529-43. doi: 10.1016/j.nlm.2011.08.003. Epub 2011 Sep 6. Review.

15.

Role of HIV in amyloid metabolism.

Ortega M, Ances BM.

J Neuroimmune Pharmacol. 2014 Sep;9(4):483-91. doi: 10.1007/s11481-014-9546-0. Epub 2014 May 10. Review.

16.

The sleep-wake cycle and Alzheimer's disease: what do we know?

Lim MM, Gerstner JR, Holtzman DM.

Neurodegener Dis Manag. 2014;4(5):351-62. doi: 10.2217/nmt.14.33. Review.

17.

Focusing the amyloid cascade hypothesis on N-truncated Abeta peptides as drug targets against Alzheimer's disease.

Bayer TA, Wirths O.

Acta Neuropathol. 2014;127(6):787-801. doi: 10.1007/s00401-014-1287-x. Epub 2014 May 7. Review.

18.

The relevance of beta-amyloid on markers of Alzheimer's disease in clinically normal individuals and factors that influence these associations.

Mormino EC.

Neuropsychol Rev. 2014 Sep;24(3):300-12. doi: 10.1007/s11065-014-9267-4. Epub 2014 Aug 10. Review.

19.

Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications.

Creed MC, Milgram NW.

Age (Dordr). 2010 Sep;32(3):365-84. doi: 10.1007/s11357-010-9142-z. Epub 2010 Apr 20. Review.

20.

Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of natural products.

Awasthi M, Singh S, Pandey VP, Dwivedi UN.

J Neurol Sci. 2016 Feb 15;361:256-71. doi: 10.1016/j.jns.2016.01.008. Epub 2016 Jan 8. Review.

PMID:
26810552

Supplemental Content

Support Center